The 36-month beta value for EVLO is also noteworthy at 1.62. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for EVLO is $6.50, which is $1.43 above than the current price. The public float for EVLO is 17.32M, and at present, short sellers hold a 1.61% of that float. The average trading volume of EVLO on September 18, 2023 was 920.32K shares.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
EVLO) stock’s latest price update
Evelo Biosciences Inc. (NASDAQ: EVLO)’s stock price has dropped by -10.42 in relation to previous closing price of 5.66. Nevertheless, the company has seen a loss of -24.55% in its stock price over the last five trading days. Seeking Alpha reported 2023-08-25 that Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or break the company. Prior failure of EVLO’s platform in atopic dermatitis is concerning. However, psoriasis is a different indication (different pathophysiology) and de-risked by positive results in a prior phase 2 study. Ongoing phase 2 trial in psoriasis is being conducted with a second generation candidate, EDP2939, which is expected to have better efficacy and now represents EVLO’s sole clinical-stage candidate.
EVLO’s Market Performance
EVLO’s stock has fallen by -24.55% in the past week, with a monthly drop of -60.97% and a quarterly rise of 205.79%. The volatility ratio for the week is 13.31% while the volatility levels for the last 30 days are 17.24% for Evelo Biosciences Inc. The simple moving average for the past 20 days is -24.36% for EVLO’s stock, with a -57.62% simple moving average for the past 200 days.
Analysts’ Opinion of EVLO
Many brokerage firms have already submitted their reports for EVLO stocks, with Chardan Capital Markets repeating the rating for EVLO by listing it as a “Buy.” The predicted price for EVLO in the upcoming period, according to Chardan Capital Markets is $12 based on the research report published on November 01, 2021 of the previous year 2021.
EVLO Trading at -32.66% from the 50-Day Moving Average
After a stumble in the market that brought EVLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.52% of loss for the given period.
Volatility was left at 17.24%, however, over the last 30 days, the volatility rate increased by 13.31%, as shares sank -59.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +92.05% upper at present.
During the last 5 trading sessions, EVLO fell by -24.55%, which changed the moving average for the period of 200-days by -87.26% in comparison to the 20-day moving average, which settled at $6.33. In addition, Evelo Biosciences Inc. saw -84.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVLO starting from McHale Duncan, who sale 3,434 shares at the price of $9.51 back on Aug 08. After this action, McHale Duncan now owns 7,941 shares of Evelo Biosciences Inc., valued at $32,657 using the latest closing price.
Bodmer Mark, the CSO, President of R&D of Evelo Biosciences Inc., sale 3,128 shares at $9.51 during a trade that took place back on Aug 08, which means that Bodmer Mark is holding 16,624 shares at $29,747 based on the most recent closing price.
Stock Fundamentals for EVLO
The total capital return value is set at -195.25, while invested capital returns managed to touch -214.28. Equity return is now at value 581.40, with -188.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.16.
Conclusion
In summary, Evelo Biosciences Inc. (EVLO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
